Sandbox/0319: Difference between revisions
< Sandbox
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{|style="margin: 0 0 0 0; border: 0; width: 900px; background: #545454; border-radius: 10px 10px 10px 10px; height: 30px; line-height: 30px;" | |||
{|style="margin: 0 0 0 0; border: 0; width: | |||
|- | |- | ||
! style="font-size: | ! style="font-size: 120%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" | {{fontcolor|#F8F8FF|FDA-Labeled Indications and Dosage (Adult)}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: # | ! style="font-size: 99%; padding: 0 5px; font-size: 90%; background: #545454; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction}} | ||
|- | |- | ||
! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #A8A8A8; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|▸ [[Fragmin injection]] 120 IU/kg SC q12h (≤10,000 IU) for 5—8 days with concurrent [[Aspirin]] 75—165 mg PO q24h}} | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: # | ! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #545454; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|Prophylaxis of Venous Thromboembolism Following Hip Replacement Surgery}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: # | ! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #A8A8A8; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|▸ [[Fragmin injection]] 2500 IU SC 4—8 hours POSToperatively followed by 5000 IU SC q24h for 5—10 days<BR> OR <BR> ▸ [[Fragmin injection]] 2500 IU SC 2 hours PREoperatively and 4—8 hours POSToperatively followed by 5000 IU SC q24h for 5—10 days<BR> OR <BR> ▸ [[Fragmin injection]] 5000 IU SC 10—14 hours PREoperatively and 4—8 hours POSToperatively followed by q24h for 5—10 days}} | ||
|- | |||
! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #545454; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|Prophylaxis of Venous Thromboembolism Following Abdominal Surgery}} | |||
|- | |||
! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #A8A8A8; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|▸ [[Fragmin injection]] 2500 IU SC q24h PREoperatively followed by q24h for 5—10 days<BR> OR <BR> ▸ [[Fragmin injection]] 5000 IU SC q24h for 5—10 days (starting the evening prior to sugery) [High Risk Patient]<BR> OR <BR> ▸ [[Fragmin injection]] 2500 IU SC PREoperatively and 2500 IU SC 12 hours later followed by 5000 IU SC q24h for 5—10 days [High Risk Patient]}} | |||
|- | |||
! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #545454; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|Medical Patients with Severely Restricted Mobility During Acute Illness}} | |||
|- | |||
! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #A8A8A8; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|▸ [[Fragmin injection]] 5000 IU SC q24h for 12—14 days}} | |||
|- | |||
! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #545454; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|Extended Treatment of Symptomatic Venous Thromboembolism in Patients with Cancer}} | |||
|- | |||
! style="font-size: 90%; padding: 0 5px; font-size: 90%; background: #A8A8A8; border-radius: 5px 5px 5px 5px;" align=left | {{fontcolor|#F8F8FF|▸ [[Fragmin injection]] 200 IU/kg SC q24h (≤18,000 IU) for 30 days followed by 150 IU/kg SC q24h from months 2—6}} | |||
|- | |- | ||
|} | |} | ||
Latest revision as of 17:25, 19 March 2014
| FDA-Labeled Indications and Dosage (Adult) |
|---|
| Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction |
| ▸ Fragmin injection 120 IU/kg SC q12h (≤10,000 IU) for 5—8 days with concurrent Aspirin 75—165 mg PO q24h |
| Prophylaxis of Venous Thromboembolism Following Hip Replacement Surgery |
| ▸ Fragmin injection 2500 IU SC 4—8 hours POSToperatively followed by 5000 IU SC q24h for 5—10 days OR ▸ Fragmin injection 2500 IU SC 2 hours PREoperatively and 4—8 hours POSToperatively followed by 5000 IU SC q24h for 5—10 days OR ▸ Fragmin injection 5000 IU SC 10—14 hours PREoperatively and 4—8 hours POSToperatively followed by q24h for 5—10 days |
| Prophylaxis of Venous Thromboembolism Following Abdominal Surgery |
| ▸ Fragmin injection 2500 IU SC q24h PREoperatively followed by q24h for 5—10 days OR ▸ Fragmin injection 5000 IU SC q24h for 5—10 days (starting the evening prior to sugery) [High Risk Patient] OR ▸ Fragmin injection 2500 IU SC PREoperatively and 2500 IU SC 12 hours later followed by 5000 IU SC q24h for 5—10 days [High Risk Patient] |
| Medical Patients with Severely Restricted Mobility During Acute Illness |
| ▸ Fragmin injection 5000 IU SC q24h for 12—14 days |
| Extended Treatment of Symptomatic Venous Thromboembolism in Patients with Cancer |
| ▸ Fragmin injection 200 IU/kg SC q24h (≤18,000 IU) for 30 days followed by 150 IU/kg SC q24h from months 2—6 |